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Abstract 
Background: Lipoprotein disturbances have been associated with increased cardiovascular disease (CVD) risk in type 
1 diabetes mellitus (T1DM). We assessed the advanced lipoprotein profile in T1DM individuals, and analysed differ‑
ences with non‑diabetic counterparts.
Methods: This cross‑sectional study involved 508 adults with T1DM and 347 controls, recruited from institutions 
in a Mediterranean region of Spain. Conventional and advanced (assessed by nuclear magnetic resonance [NMR] 
spectroscopy) lipoprotein profiles were analysed. Crude and adjusted (by age, sex, statin use, body mass index and 
leukocyte count) comparisons were performed.
Results: The median (interquartile range) age of the study participants was 45 (38–53) years, 48.2% were men. In the 
T1DM group, the median diabetes duration was 23 (16–31) years, and 8.1% and 40.2% of individuals had nephropathy 
and retinopathy, respectively. The proportion of participants with hypertension (29.5 vs. 9.2%), and statin use (45.7% 
vs. 8.1%) was higher in the T1DM vs. controls (p < 0.001). The T1DM group had a better conventional (all parameters, 
p < 0.001) and NMR‑lipid profile than the control group. Thus, T1DM individuals showed lower concentrations of ath‑
erogenic lipoproteins (VLDL‑particles and LDL‑particles) and higher concentrations of anti‑atherogenic lipoproteins 
(HDL‑particles) vs. controls, even after adjusting for several confounders (p < 0.001 for all). While non‑diabetic women 
had a more favourable lipid profile than non‑diabetic men, women with T1DM had a similar concentration of LDL‑par‑
ticles compared to men with T1DM (1231 [1125–1383] vs. 1257 [1128–1383] nmol/L, p = 0.849), and a similar concen‑
tration of small‑LDL‑particles to non‑diabetic women (672.8 [614.2–733.9] vs. 671.2 [593.5–761.4] nmol/L, respectively; 
p = 0.790). Finally, T1DM individuals showed higher discrepancies between NMR‑LDL‑particles and conventional LDL‑
cholesterol than non‑diabetic subjects (prevalence of LDL‑cholesterol < 100 mg/dL & LDL‑particles > 1000 nmol/L: 38 
vs. 21.2%; p < 0.001). All these differences were largely unchanged in participants without lipid‑lowering drugs (T1DM, 
n = 275; controls, n = 317).
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Background
Cardiovascular disease (CVD) is still the leading cause 
of morbidity and mortality among the type 1 diabetes 
mellitus (T1DM) population [1]. Glycaemic control has 
been strongly associated with CVD risk [2]. However, 
even in those individuals with well-controlled T1DM 
(mean HbA1c < 7%), CVD death is roughly threefold 
higher compared with their non-diabetic counterparts 
[2]. Thus, other non-glycaemic CVD risk factors are 
involved in this accelerated atherosclerosis [3–5]. Among 
them, lipoprotein disturbances, especially LDL-choles-
terol, are thought to be strongly related with CVD in this 
population. In fact, in a large cohort study, an increase 
of 1  mmol/L of LDL-cholesterol was associated with a 
35% to 50% greater risk of overall CVD [6]. In addition, 
other lipid parameters such as HDL-related variables [7] 
and triglyceride values [8] have also been associated with 
CVD risk in T1DM individuals.
Advancing the understanding of the underlying lipo-
protein disturbances, therefore, seems to be crucial to 
tackle CVD in this high-risk population beyond glycae-
mic control [8]. However, the information regarding the 
differences in the lipoprotein profile among T1DM vs. 
their non-diabetic counterparts is scarce and conflicting 
results are reported [9–11]. In addition, advanced proce-
dures to study these lipoprotein differences in depth (i.e., 
nuclear magnetic resonance (NMR) spectroscopy) have 
been used in only a few studies, with small samples and 
heterogeneous results [12–15]. Furthermore, the only 
NMR study that recruited a large number of participants 
was from more than 15  years ago, which may therefore 
not be representative of the current T1DM population 
[16]. Thus, there is currently little robust evidence to 
draw any reliable conclusions regarding the T1DM-dif-
ferential lipoprotein profile, especially in relation to con-
temporary cohorts and using advanced analytical tools.
Against this background, the aim of this study was to 
assess the advanced lipoprotein profile in T1DM indi-
viduals, and to identify differences with non-diabetic 
counterparts. In addition, we further analysed the differ-
ential associations between these NMR-related param-
eters with other common variables, such as age, gender, 
or anthropometric or other laboratory measurements. 
Finally, since LDL-cholesterol has been strongly associ-
ated with CVD, both in the general [17] and in the T1DM 
population [6], the differences in the conventional vs. 




In this cross-sectional study, 855 participants were 
selected from previous studies [4, 18, 19], including 508 
individuals with T1DM and 347 without diabetes. This 
study was planned as a collaborative study that included 
participants from different cohorts from participat-
ing institutions from the Catalonia region of Spain that 
belong to the same health care organisation. All potential 
participants (n = 508) were identified from the electronic 
clinical records from the participating institutions.
The study involved three cohorts: the University Hospi-
tal Germans Trias i Pujol [UHGTiP] and University Hos-
pital Arnau de Vilanova [UHAV] cohort; Hospital Clínic 
of Barcelona (HCB) cohort; and the Mollerusa cohort. 
Participants with T1DM were recruited from the diabetic 
outpatient clinics at UHGTiP-UHAV (n = 319; represent-
ing 63% of the T1DM sample), and HCB (n = 189; 37% of 
the T1DM sample). Participants without diabetes were 
from the UHGTiP-UHAV cohort (n = 192) and the Mol-
lerussa cohort (n = 155). All the participants had avail-
able stored blood samples collected at the inclusion in 
each cohort.
T1DM participants included were > 18  years-old, with 
T1DM duration of at least 1 year, and with no evidence 
of previous CVD, defined as any form of clinical coro-
nary heart disease, stroke or peripheral vascular dis-
ease (including any form of diabetic foot disease). For 
T1DM participants from the first two institutions 
(UHGTiP-UHAV), additional inclusion criteria were as 
follows: a) normal renal function (estimated glomeru-
lar filtration rate [eGFR] > 60  mL/min), and b) albumin-
to-creatinine ratio < 300  mg/g. For T1DM from HCB, 
additional inclusion criteria were: a) age ≥ 40  years; b) 
presence of any stage of diabetic nephropathy, irrespec-
tive of the age of the subject and diabetes duration; and/
or  c) ≥ 10  years of duration of T1DM  with at least one 
Conclusions: Overall, T1DM participants showed a more favourable conventional and NMR‑lipid profile than con‑
trols. However, the NMR‑assessment identified several lipoprotein derangements in LDL‑particles among the T1DM 
population (higher discrepancies in NMR‑LDL‑particles vs. conventional LDL‑cholesterol; a worse profile in T1DM 
women) that were overlooked in the conventional analysis. Further studies are needed to elucidate their role in the 
development of CVD in this population.
Keywords: Type 1 diabetes, Lipoproteins, Advanced lipoprotein profile, Nuclear magnetic resonance spectroscopy, 
LDL‑particles
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additional CVD risk factor (defined as either any of 
the following: retinopathy,  family  history of premature 
CVD in first degree relatives (defined as any CVD occur-
ring before 55  years of age in men and before 65  years 
of age in women [20],  active smoking habit, hyperten-
sion, low high-density lipoprotein cholesterol (HDL-
cholesterol; < 40 mg/dL in males, < 45 mg/dL in females), 
triglycerides > 150 mg/d, the presence of severe hypogly-
cemia events or hypoglycemia unawareness, and women 
with a history of preeclampsia/eclampsia in at least one 
pregnancy). For the control group, participants were 
selected who had fasting glucose and HbA1c values 
below 100 mg/dl and 5.7% (39 mmol/mol), respectively, 
and with an available sample to assess lipoproteins. These 
non-diabetic subjects were free from CVD and had nor-
mal renal function as described above.
Clinical and laboratory determinations
Age, sex, smoking habit (current, former or never 
smoker), and pharmacological treatment (especially 
focused on cardioprotective drugs) were recorded. 
T1DM duration was extracted from the medical records. 
Anthropometric data (weight, height and body mass 
index [BMI]) were obtained using standard methods. 
Waist circumference was measured to the nearest 0.5 cm 
using an anthropometric tape midway between the low-
est rib and the iliac crest at minimal respiration. Blood 
pressure was registered after a few minutes of rest.
The diagnosis of diabetic retinopathy was obtained 
from medical records and was always verified by an 
ophthalmologist. Diabetic nephropathy was defined as 
a persistent abnormally increased creatinine-to-albu-
min ratio (≥ 30 mg/g) or receiving treatment with angi-
otensin-converting enzyme inhibitors or angiotensin 
receptor blockers for this reason. Obesity was defined 
as a BMI ≥ 30  kg/m2, and central obesity as a waist cir-
cumference ≥ 88  cm in women and ≥ 102  cm in men 
[21]. In both groups, hypertension was defined as the 
use of antihypertensive drugs or repeated clinical sys-
tolic blood pressure ≥ 140  mmHg or diastolic blood 
pressure ≥ 90 mmHg.
After at least 10–12 h of overnight fasting and without 
any concurrent stress the day before (minor illness, stren-
uous exercise, etc.), blood and first morning urine spot 
samples were collected and analysed in local laboratories 
according to standard procedures. Total cholesterol, tri-
glycerides and HDL-cholesterol were measured directly, 
whereas LDL-cholesterol was estimated using the Friede-
wald formula. Plasma glucose concentrations were meas-
ured using the glucose oxidase method, and haemoglobin 
A1c (HbA1c) levels were measured using a high perfor-
mance liquid chromatography method (expressed in the 
National Glycohemoglobin Standardization Program/
Diabetes Control and Complications Trial units). Cre-
atinine was assessed by the Jaffe method and urine albu-
min using an immunoturbidimetric assay. Finally, hepatic 
profile parameter values were determined by molecular 
absorption spectrometry, and inflammation markers 
(leukocyte count and high sensitivity C-reactive protein 
[hsCRP]) by flow cytometry and immunoturbidimetric 
assay, respectively.
Low HDL-cholesterol was defined as < 50  mg/dL in 
women and < 40  mg/dL in men; and high triglycerides 
as ≥ 150  mg/dL [21]. Non-HDL-cholesterol was calcu-
lated as total cholesterol minus HDL-cholesterol; and 
remnant cholesterol as total cholesterol minus HDL-
cholesterol minus LDL-cholesterol [22]. The eGFR was 
obtained using the Chronic Kidney Disease-Epidemi-
ology Collaboration equation (CKD-EPI) [23]. Fatty 
liver index (FLI) was used as a surrogate of non-alco-
holic liver disease, calculated as:  (e0.953 * Loge(triglycerides) + 
0.139 * BMI + 0.718 * Loge(GGT) + 0.053 * (waist circumference)−15.745)/
(1 + e 0.953 * Loge(triglycerides) + 0.139 * BMI + 0.718 * Loge(GGT) + 
0.053 * (waist circumference)−15.745) * 100 [24]. Accordingly, 
hepatic steatosis was defined as a FLI > 60 [24]. Finally, 
in the T1DM group insulin sensitivity was estimated 
using the following equation that has previously been 
validated against euglycemic-hyperinsulinemic clamps: 
(log insulin sensitivity = 4.64725 − 0.02032 × waist cir-
cumference in cm − 0.00235 × triglycerides in mg/
dL − 20.09779 × HbA1c in  % [25].
Lipoprotein analysis by NMR spectroscopy (advanced 
lipoprotein profile)
Lipoprotein analysis of plasma samples by 2-dimen-
sional diffusion-ordered 1H-NMR spectroscopy (DOSY) 
was performed as previously described [26]. This proto-
col evaluates the lipid concentrations (i.e., triglycerides 
and cholesterol), size and particle number of 3 different 
classes of lipoproteins (VLDL, LDL, and HDL), as well as 
the particle number of 9 subclasses (large, medium and 
small VLDL, LDL, and HDL). Briefly, the methyl signal 
of the plasma 2D 1H-NMR spectra was deconvoluted by 
using 9 Lorentzian functions to determine the lipid con-
centration of the large, medium and small subclasses of 
the main lipoprotein classes (VLDL, LDL, and HDL), and 
the diffusion coefficient associated with each analytical 
function, which is associated with the size. Finally, we 
combined the lipid concentration and geometric infor-
mation (DC derived particle volume) in order to quantify 
the number of particles required to transport the meas-
ured lipid concentration of each lipoprotein subclass. 
Finally, weighted average VLDL, LDL, and HDL particle 
sizes were calculated from the subclass concentrations by 
summing the known diameter of each subclass multiplied 
by its relative percentage of subclass particle number. 
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The mean particle diameter for the subclasses (and the 
estimated ranges) were as follows: large VLDL particles 
(VLDL-P), 75.2 nm (> 60 nm); medium VLDL-P, 52.1 nm 
(45–60  nm); small VLDL-P, 37.1  nm (35–45  nm); large 
LDL particles (LDL-P), 22.8  nm (22.5–27  nm); medium 
LDL-P, 20.5  nm (20–22.5  nm); small LDL-P 18.9  nm 
(18–20  nm); large HDL particles (HDL-P), 10.1  nm 
(9–13  nm); medium HDL-P, 8.7  nm (8.2–9  nm); small 
HDL-P, 7.8  nm (< 8.2  nm). Finally, cholesterol and tri-
glyceride content of each lipoprotein class was also deter-
mined by using NMR-based  Liposcale® test [26]. All the 
samples were separated by centrifugation and appropri-
ately frozen at − 80 °C from their collection, without any 
previous defrosting procedure before the analysis.
Statistical analyses
Data are presented as median and 25th and 75th percen-
tiles, mean ± standard deviation, or number (percentage) 
unless otherwise indicated. The normal distribution of 
continuous variables was assessed using the Kolmogo-
rov–Smirnov test. Non-normally distributed variables 
were log transformed to reduce skewness when appropri-
ate. Between-group differences (control vs. T1DM group) 
in clinical, laboratory and conventional lipid variables 
were evaluated using the Chi squared test for categorical 
variables, the Mann–Whitney test for continuous non-
normally distributed variables, or the unpaired Student’s 
t test for continuous normally distributed variables.
Spearman correlation analyses were used to assess rela-
tionships between all NMR-assessed lipoproteins and 
age, anthropometric parameters (BMI and waist circum-
ference), systolic blood pressure, several parameters for 
kidney function (eGFR and albumin-to-creatinine ratio), 
inflammation variables (leukocyte count and hsCRP), 
markers of fatty liver disease (alanine aminotransferase 
and FLI) and T1DM-specific variables (diabetes dura-
tion, HbA1c, insulin dose and insulin sensitivity surro-
gates). Differences in NMR-related variables according 
to study group were also assessed using parametric and 
non-parametric tests, as appropriate. In addition, analy-
sis of covariance (ANCOVA) was used for adjusting 
these differences by age, sex and lipid-lowering drugs 
(model 1), and additionally by BMI and leukocyte count 
(model 2). The variables included in the models were 
selected according to the prior knowledge [27, 28], or 
after evaluating the significative correlations with NRM-
lipoproteins found in our sample of participants. Further 
between-group differences in NMR-lipoprotein vari-
ables were performed only in participants without lipid-
lowering drugs, or according to gender, smoking habit or 
chronic diabetic complications (i.e., diabetic nephropathy 
and retinopathy). Finally, concordance between conven-
tional LDL-cholesterol and NRM-LDL-P according to 
the study group was also assessed, either as a continuous 
variable (Spearman correlation analysis), or using a cut-
off of 100 mg/dL (for LDL-cholesterol) and 1000 nmol/L 
(for LDL-P). The two-sided significance level was set as 
p < 0.05. All statistical analyses were performed using the 
SPSS 20.0 statistical package (Chicago, IL).
Results
Participants’ characteristics
Eight hundred and fifty-five participants were included in 
the study. The median age of the whole sample popula-
tion was 45.2 (38.0–53.0) years and 51.8% were women. 
The differences between those without diabetes (n = 347) 
vs. those with T1DM (n = 508) are shown in Table 1. All 
the T1DM participants were on intensified insulin ther-
apy (either basal-bolus or continuous subcutaneous insu-
lin infusion therapy), > 99% of them on insulin analogs. 
The median age, BMI, blood pressure and the proportion 
of men were significantly higher among T1DM individu-
als (p < 0.05 for all comparisons), with no significant dif-
ferences in smoking habit and waist circumference. Statin 
use was also higher in T1DM individuals (45.7 vs. 8.1%; 
p < 0.001), without gender differences (men vs. women: 
46.7% vs. 44.5%, p = 0.617 in the T1DM group, and 7.9% 
vs. 8.2%, p = 0.942 in the control group). Regarding labo-
ratory characteristics, T1DM individuals showed higher 
values of some inflammation-related markers (i.e., leuko-
cyte count; p = 0.004). As would be expected, glycaemic-
related variables (fasting plasma glucose and HbA1c) 
were also higher in the T1DM group (p < 0.001).
Baseline differences in the two cohorts of T1DM 
patients (UHGTiP-UHAV vs. HCB) were further 
assessed. There were no differences between cohorts 
in terms of age, main CVD risk factors, microvascu-
lar complications and statin use (p > 0.125 for all com-
parisons). The participants from the HCB cohort had a 
higher proportion of males (47.6 vs. 57.7%; p = 0.029), 
longer diabetes duration (mean [SD]: 20.0 [14.0–29.0] vs. 
26.5 [20.6–33.4] years; p < 0.001), and some minor dif-
ferences in other laboratory parameters (kidney-, liver- 
and inflammation-derived variables; Additional file  1: 
Table S1).
Conventional and advanced lipoprotein profile in T1DM vs. 
controls
The conventional lipid profile according to diabetes sta-
tus is shown in Table 1. Lipid concentrations were lower 
in T1DM individuals (p < 0.05 for all), with the excep-
tion of HDL-cholesterol (higher in T1DM; p = 0.035). 
No major differences were found after excluding those 
participants on lipid-lowering drugs (n = 33 and n = 233, 
for the control and T1DM groups, respectively), except 
for HDL-cholesterol, which was no longer statistically 
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Table 1 Differences in clinical and laboratory characteristics in study participants
Data are shown as n (percentage), mean ± standard deviation or median (Q1-Q3)
p values for group comparisons are reported
BMI Body Mass Index, DBP diastolic blood pressure, CSII continuous subcutaneous insulin insfusion, eGFR estimated glomerular filtration rate, HDL high density 
lipoprotein, hsCRP high sensitivity C-reactive protein, LDL low density lipoprotein, SBP systolic blood pressure; T1DM type 1 diabetes mellitus
a Missing values; n = 5 and n = 0
b Defined as ≥ 88 cm in women and ≥ 102 cm in men. Missing values, n = 10 and n = 15
c Missing values n = 3
d Missing values n = 10
e Defined as HDL-cholesterol < 50 in women and < 40 mg/dL in men
f Missing values n = 162 and n = 75
g Missing values n = 13 and n = 76
Controls T1DM p value
(n = 347) (n = 508)
Clinical characteristics
 Gender (male) 151 (43.5) 261 (51.4) 0.024
 Age (years) 44.0 (37.0–52.0) 46.0 (39.2–54.0) 0.005
 Never smokers 160 (46.1) 248 (48.8) 0.436
 Hypertension 32 (9.2) 150 (29.5) < 0.001
 SBP (mmHg) 120 (110–130) 127 (116–138) < 0.001
 DBP (mmHg) 75 (70–81) 77 (70–83) 0.044
 BMI (kg/m2) 24.9 (22.8–27.8) 25.7 (23.1–28.4) 0.022
  Obesity (BMI ≥ 30 kg/m2)a 42 (12.3) 85 (16.7) 0.074
 Waist circumference (cm) 90 (82–99) 89 (82–99) 0.547
  Central  obesityb 127 (37.7) 171 (34.7) 0.376
 Diabetes duration (years) – 23.0 (16.0–31.0) –
 Diabetic  nephropathyc – 41 (8.1) –
 Diabetic  retinopathyd – 200 (40.2) –
 Statin use 28 (8.1) 232 (45.7) < 0.001
 CSII therapy – 116 (22.8) –
Conventional lipid profile
 Total cholesterol (mg/dL) 193 (172–219) 179 (161–202) < 0.001
 HDL‑cholesterol (mg/dL) 58 (49–68) 60 (50–72) 0.035
  Low HDL‑cholesterol (mg/dL)e 45 (13.0) 50 (9.9) 0.153
 LDL‑cholesterol (mg/dL) 116 (96–137) 103 (86–119) < 0.001
  LDL‑cholesterol < 100 mg/dL 100 (29.1) 226 (44.8) < 0.001
  LDL‑cholesterol < 70 mg/dL 19 (5.5) 36 (7.1) 0.351
 Triglycerides (mg/dL) 85 (63–118) 70 (54–90) < 0.001
  Triglycerides ≥ 150 mg/dL 53 (15.4) 33 (6.5) < 0.001
 Non‑HDL cholesterol (mg/dL) 136 (113–160) 117 (100–136) < 0.001
 Remnant cholesterol (mg/dL) 17 (13–23) 14 (11–18) < 0.001
Other laboratory characteristics
 Fasting plasma glucose (mg/dL) 87 (82–94) 150 (108–201) < 0.001
 Haemoglobin A1c (%) 5.4 (5.1–5.6) 7.4 (7.0–8.1) < 0.001
 Serum creatinine (mg/dL) 0.77 (0.67–0.89) 0.79 (0.68–0.91) 0.261
 eGFR (CKD‑EPI; ml/min/1.73 m2) 103 (90–111) 101 (90–110) 0.29
 Alanine aminotransferase 17 (13–23) 18 (14–24) 0.021
 γ‑glutamyl transpeptidase 17 (12–25) 17 (12–24) 0.761
 Leukocyte count (per  mm3) 6100 (5000–7307) 6400 (5300–8012) 0.004
 hsCRP (mg/L)f 1.13 (0.50–2.03) 1.29 (0.60–2.80) 0.088
 Albumin‑to‑creatinine ratio 2.8 (1.4–5.0) 4.0 (2.0–7.0) <0.001
 Fatty liver  indexg 23.5 (10.1–54.8) 22.8 (10.2–47.4) 0.48
  Fatty liver index > 60 67 (19.3) 71 (14.0) 0.037
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significant (58 [49–68] vs. 59.5 [50.7–73] mg/dL, in con-
trols vs. T1DM, respectively; p = 0.065).
The NMR advanced lipoprotein profile showed fur-
ther differences (Table 2). Thus, VLDL-P and LDL-P lipid 
content (both cholesterol and triglycerides), and total 
particle number and subclasses were significantly lower 
in the T1DM group (all p < 0.01). Regarding HDL, most 
of the related variables were higher in the T1DM group 
Table 2 NMR-assessed advanced lipoprotein profile in control and T1DM groups
Data are shown as median (Q1–Q3) or mean ± standard deviation
*p-value adjusted for age, sex, and lipid-lowering medications
† p-value adjusted for age, sex, lipid-lowering medications, BMI and leukocyte count
HDL high-density lipoprotein, HDL-C cholesterol content in HDL, HDL-P HDL particles, HDL-TG triglyceride content in HDL, LDL low-density lipoprotein, LDL-C 
cholesterol content in LDL, LDL-P LDL particles, LDL-TG triglyceride content in LDL, NMR nuclear magnetic resonance, T1DM type 1 diabetes mellitus, VLDL very low-
density lipoprotein, VLDL-C cholesterol content in VLDL, VLDL-P VLDL particles, VLDL-TG triglyceride content in VLDL
NMR variable Controls T1DM p p* p†
(n = 347) (n = 508)
VLDL‑P number (nmol/L)
 Total 36.5 (25.5–53.3) 29.1 (22.8–37.7) < 0.001 < 0.001 < 0.001
 Large 0.93 (0.71–1.24) 0.82 (0.63–1.04) < 0.001 < 0.001 < 0.001
 Medium 3.92 (2.62–5.50) 2.80 (1.88–4.28) < 0.001 < 0.001 < 0.001
 Small 31.4 (22.1–47.0) 25.4 (20.1–32.5) < 0.001 < 0.001 < 0.001
 Ratio large/total 0.025 (0.023–0.027) 0.027 (0.025–0.030) < 0.001 < 0.001 < 0.001
VLDL‑P composition (mg/dL)
 VLDL‑C 9.94 (5.44–16.11) 7.78 (4.42–11.80) 0.001 < 0.001 < 0.001
 VLDL‑TG 52.8 (36.5–75.3) 41.0 (32.2–53.5) < 0.001 < 0.001 < 0.001
 Ratio VLDL‑C/VLDL‑TG 0.17 (0.13–0.21) 0.19 (0.13–0.23) 0.003 0.056 0.075
VLDL‑P size (nm) 42.1 (42.0–42.3) 42.1 (41.9–42.3) 0.348 0.502 0.469
LDL‑P number (nmol/L)
 Total 1356.2 (1159.3–1567.7) 1244.6 (1127.7–1382.6) < 0.001 < 0.001 < 0.001
 Large 191.9 (167.6–217.6) 175.7 (159.9–195.2) < 0.001 < 0.001 < 0.001
 Medium 437.6 (344.6–531.3) 373.4 (315.5–461.0) < 0.001 < 0.001 < 0.001
 Small 708.6 (623.5–827.3) 684.1 (622.0–751.7) 0.001 < 0.001 < 0.001
 Ratio small/total 0.53 (0.49–0.58) 0.55 (0.51–0.59) < 0.001 0.094 0.098
LDL‑P composition (mg/dL)
 LDL‑C 132.9 (113.5–154.2) 122.4 (110.1–137.0) < 0.001 < 0.001 < 0.001
 LDL‑TG 16.6 (13.4–20.4) 14.6 (12.5–17.6) < 0.001 < 0.001 < 0.001
 Ratio LDL‑C/LDL‑TG 8.20 (7.25–9.13) 8.25 (7.35–9.60) 0.042 0.003 0.003
LDL‑P size (nm) 21.0 ± 0.27 21.0 ± 0.27 0.35 0.163 0.142
HDL‑P number (μmol/L)
 Total 29.0 (26.0–33.2) 31.8 (29.2–36.0) < 0.001 < 0.001 < 0.001
 Large 0.26 (0.23–0.30) 0.27 (0.25–0.31) 0.002 < 0.001 < 0.001
 Medium 9.12 (7.90–10.60) 10.47 (9.19–12.11) < 0.001 < 0.001 < 0.001
 Small 19.9 (17.4–22.8) 20.9 (18.5–23.8) 0.001 0.009 0.005
 Ratio small/total 0.67 (0.64–0.71) 0.66 (0.63–0.69) < 0.001 < 0.001 < 0.001
HDL‑P composition (mg/dL)
 HDL‑C 56.2 (49.2–65.5) 63.0 (54.9–73.3) < 0.001 < 0.001 < 0.001
 HDL‑TG 12.7 (10.3–15.7) 14.7 (12.2–17.7) < 0.001 < 0.001 < 0.001
 Ratio HDL‑C/HDL‑TG 4.49 (3.61–5.52) 4.32 (3.58–5.31) 0.101 0.315 0.215
HDL‑P size (nm) 8.21 ± 0.06 8.25 ± 0.07 < 0.001 < 0.001 < 0.001
Other atherogenic variables
 Non‑HDL‑P (nmol/L) 1377.2 (1170.7–1578.5) 1239.8 (1128.6–1382.4) < 0.001 < 0.001 < 0.001
 Ratio LDL‑P/HDL‑P 46.1 (37.2–56.7) 39.4 (33.3–45.5) < 0.001 < 0.001 < 0.001
 Ratio total‑P/HDL‑P 47.7 (38.3–58.4) 40.4 (34.0–46.7) < 0.001 < 0.001 < 0.001
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(i.e., the particle number and subclasses, and lipid con-
tent; p < 0.01 for all comparisons). Consequently, several 
atherogenic lipid markers were also found to be lower 
in the T1DM group (p < 0.001). VLDL-P and LDL-P size 
was similar, and HDL-P size higher, in the T1DM group. 
No differences were observed after adjusting for age, gen-
der, statin use, BMI or leukocyte count (Table 2). These 
differences in the NMR lipoprotein profile were also 
assessed only in the participants without lipid-lowering 
treatment (for the characteristics, see Additional file  2: 
Table S2). Overall, all the changes described above in the 
whole sample of individuals regarding T1DM vs. controls 
remained unchanged in the participants without lipid-
lowering treatment (Table 3).
As an additional analysis, the NMR-variables between 
the two T1DM cohorts (UHGTiP-UHAV and HCB 
cohorts) were also compared. Compared to the HCB 
cohort group, the UHGTiP-UHAV cohort group showed 
lower concentrations of VLDL-P and higher concentra-
tions of HDL-P (p < 0.01 for all), but similar amounts of 
total LDL-P and non-HDL-P (p > 0.800 for both); this is 
in accordance with the conventional lipid profile (Addi-
tional file 1: Table S1). Sex-adjusted models blunted some 
of these differences, especially in HDL-related variables. 
Both T1DM cohorts compared separately to the con-
trol group showed similar results to that observed in the 
whole T1DM group (Additional file 3: Table S3).
Sex and age differences in the NMR advanced lipoprotein 
profile
With regard to sex comparisons within the same-group 
(either control or T1DM), women showed lower val-
ues of VLDL and higher values of HDL-related variables 
(all p < 0.05, Table  4). LDL-P was significantly lower in 
women vs. men in the control group (1413 [1204–1624] 
vs. 1315 [1136–1506] nmol/L; p = 0.003], but there were 
no such significant differences in the T1DM group (1257 
[1128–1383] vs. 1231 [1125–1383]; p = 0.849). Similarly, 
non-HDL-P was significantly lower in women vs. men in 
the control group (p < 0.001), but not in the T1DM group 
(p = 0.342). In same-sex comparisons across groups, all 
the main variables were lower in men or women from 
the T1DM group (all p < 0.001), except for small LDL-P 
in women (671.2 [593.5–761.4] vs. 672.8 [614.2–733.9] 
nmol/L, for the control and T1DM groups, respectively; 
p = 0.790). No major changes were found in those par-
ticipants without lipid-lowering drugs (Additional file 4: 
Table S4).
Overall, in both groups there was a direct relation-
ship between age and HDL-related variables, whereas 
stronger and direct relationships in LDL-related param-
eters were only observed in the control group (Fig.  1). 
After dividing the sample into age quintiles, different 
patterns were found in the control vs. T1DM groups 
according to sex (Additional file  5: Fig.  S1). In statin-
adjusted models, VLDL-P concentrations (and their 
lipid content) were lower, and HDL-P concentrations 
(and their cholesterol content) were higher in women vs. 
men in both groups, and also in the T1DM group vs. the 
control group, in almost all the age ranges. LDL-related 
particles (LDL-P and LDL-C) showed a different pattern. 
In the control group, men had a marked increase in the 
levels of LDL-related variables between the ages of 36 to 
48 years (being significantly higher than women), with a 
stepped decrease after this age range. Women in the con-
trol group, however, showed a stepped increase over all 
the age ranges (p < 0.01), with a similar number of par-
ticles and cholesterol content than men from the age of 
48 years. In the T1DM group there were blunted changes 
in these variables across the age ranges, as well as lower 
between-gender differences. In fact, LDL-P and LDL-C 
was only higher in men (vs. women) in the age range 
of 36–42  years, while in participants > 56  years both 
parameters were significantly higher in T1DM women. 
Non-HDL-P followed the same pattern as LDL-related 
parameters, being also higher in women (vs. men) only in 
T1DM participants over 56 years-old.
Relationships between the advanced lipoprotein profile 
and other variables
The relationships between the NMR advanced lipopro-
tein profile according to several traits are shown in Fig. 1. 
In both the control and T1DM groups, BMI, waist cir-
cumference, and FLI were the variables most strongly 
associated with NMR variables, directly with VLDL-
related variables, small LDL-P and non-HDL-P, and 
inversely with HDL-related parameters. Weaker asso-
ciations were found with inflammation-related mark-
ers (i.e. leukocyte count and hsCRP), especially with the 
VLDL-related variables (direct). Regarding T1DM-spe-
cific variables, there were no associations with diabetic 
nephropathy measurements (Fig. 1b) or retinopathy (data 
not shown), although both diabetes duration (r = 0.2–0.3 
for HDL-TG or HDL size; Fig. 1b) and glycaemic control 
(r = 0.2–0.3 for total LDL-P and small LDL-P; Fig.  1b) 
were associated with some NMR-lipoproteins. In fact, 
the stratification of T1DM participants according to 
HbA1c concentrations (< 7, 7–8.5 and > 8.5%) revealed a 
stepped increase in the atherogenic particles (VLDL-P, 
LDL-P and non-HDL-P; p < 0.05 for all), and a decrease 
in HDL size (p < 0.01; Additional file  6: Table  S5) with 
increasing HbA1c values. Other T1DM-specific variables 
also showed strong correlations with lipoproteins, espe-
cially insulin sensitivity markers (r > 0.4 for VLDL-related 
variables; r = 0.2–0.3 for some HDL-variables; Fig.  1b). 
No major differences were found in participants without 
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lipid-lowering drugs (Additional file  7: Fig.  S2). Finally, 
while no differences were found in the control group, the 
group with T1DM individuals with an active smoking 
habit showed significantly lower levels of HDL-P (32.1 
[28.9–36.4] vs. 30.6 [26.3–34.8] μmol/L; p = 0.037 in mul-
tivariate-adjusted models; data not shown).
Table 3 NMR-assessed advanced lipoprotein profile in participants without lipid-lowering drugs
Data are shown as median (Q1–Q3) or mean ± standard deviation
*p-value adjusted for age and sex
† p-value adjusted for age, sex, BMI and leukocyte count
HDL high-density lipoprotein, HDL-C cholesterol content in HDL, HDL-P HDL particles, HDL-TG triglyceride content in HDL, LDL low-density lipoprotein, LDL-C 
cholesterol content in LDL, LDL-P LDL particles, LDL-TG triglyceride content in LDL, NMR nuclear magnetic resonance, T1DM type 1 diabetes mellitus, VLDL very low-
density lipoprotein, VLDL-C cholesterol content in VLDL, VLDL-P VLDL particles, VLDL-TG triglyceride content in VLDL
NMR variable Controls T1DM p p* p†
(n = 317) (n = 275)
VLDL‑P number (nmol/L)
 Total 36.0 (25.3–52.4) 27.6 (21.6–36.0) < 0.001 < 0.001 < 0.001
 Large 0.93 (0.69–1.22) 0.76 (0.60–1.03) < 0.001 < 0.001 < 0.001
 Medium 3.88 (2.53–5.43) 2.68 (1.87–4.18) < 0.001 < 0.001 < 0.001
 Small 31.3 (21.9–45.4) 23.8 (19.1–30.7) < 0.001 < 0.001 < 0.001
 Ratio large/total 0.025 (0.023–0.028) 0.027 (0.025–0.030) < 0.001 < 0.001 < 0.001
VLDL‑P composition (mg/dL)
 VLDL‑C 9.85 (5.37–15.76) 7.22 (4.16–11.70) 0.002 0.001 0.001
 VLDL‑TG 52.0 (36.4–73.9) 38.2 (30.8–50.3) < 0.001 < 0.001 < 0.001
 Ratio VLDL‑C/VLDL‑TG 0.17 (0.13–0.21) 0.19 (0.13–0.23) 0.007 0.047 0.054
VLDL‑P size (nm) 42.1 (42.0–42.3) 42.1 (41.9–42.3) 0.877 0.352 0.351
LDL‑P number (nmol/L)
 Total 1342.6 (1159.1–1551.7) 1276.8 (1151.7–1406.0) < 0.001 0.001 < 0.001
 Large 191.9 (167.8–216.5) 181.7 (167.1–203.0) 0.002 0.015 0.01
 Medium 433.6 (345.2–522.9) 391.8 (331.6–471.6) < 0.001 0.006 0.003
 Small 707.2 (618.9–815.2) 686.9 (620.7–755.0) 0.035 0.013 0.004
 Ratio small/total 0.53 (0.49–0.58) 0.54 (0.51–0.57) 0.058 0.134 0.138
LDL‑P composition (mg/dL)
 LDL‑C 132.5 (113.4–152.6) 126.0 (114.4–138.6) 0.004 0.014 0.006
 LDL‑TG 16.2 (13.3–20.1) 14.4 (12.4–17.8) < 0.001 < 0.001 < 0.001
 Ratio LDL‑C/LDL‑TG 8.30 (7.29–9.21) 8.61 (7.54–9.95) 0.003 0.006 0.007
LDL‑P size (nm) 21.0 ± 0.27 21.1 ± 0.24 0.388 0.185 0.158
HDL‑P number (μmol/L)
 Total 28.7 (25.7–33.02) 31.1 (27.5–35.6) < 0.001 < 0.001 < 0.001
 Large 0.26 (0.23–0.30) 0.28 (0.25–0.31) 0.001 < 0.001 < 0.001
 Medium 9.04 (7.88–10.62) 10.43 (9.15–12.24) < 0.001 < 0.001 < 0.001
 Small 19.7 (17.1–22.7) 20.4 (17.9–23.2) 0.079 0.018 0.012
 Ratio small/total 0.67 (0.64–0.71) 0.65 (0.62–0.68) < 0.001 < 0.001 < 0.001
HDL‑P composition (mg/dL)
 HDL‑C 56.1 (49.0–65.5) 63.0 (54.6–73.8) < 0.001 < 0.001 < 0.001
 HDL‑TG 12.5 (10.1–15.6) 13.7 (11.4–16.2) < 0.001 < 0.001 < 0.001
 Ratio HDL‑C/HDL‑TG 4.58 (3.63–5.59) 4.64 (3.80–5.68) 0.494 0.427 0.364
HDL‑P size (nm) 8.21 ± 0.06 8.25 ± 0.07 < 0.001 < 0.001 < 0.001
Other atherogenic variables
 Non‑HDL‑P (nmol/L) 1369.5 (1169.6–1574.9) 1274.6 (1154.1–1406.9) < 0.001 < 0.001 < 0.001
Ratio LDL‑P/HDL‑P 47.4 (38.5–58.3) 41.9 (35.5–48.5) < 0.001 < 0.001 < 0.001
 Ratio total‑P/HDL‑P 45.9 (37.4–56.4) 41.1 (34.6–47.1) < 0.001 < 0.001 < 0.001
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Table 4 NMR-assessed advanced lipoprotein profile in control and T1DM groups according to gender
Data are shown as median (Q1–Q3) or mean ± standard deviation
No differences in the statin use between gender (p = 0.942 and p = 0.617, for the control and T1DM group, respectively)
HDL high-density lipoprotein, HDL-C cholesterol content in HDL, HDL-P HDL particles, HDL-TG triglyceride content in HDL, LDL low-density lipoprotein, LDL-C 
cholesterol content in LDL, LDL-P LDL particles, LDL-TG triglyceride content in LDL, NMR nuclear magnetic resonance, T1DM type 1 diabetes mellitus, VLDL very low-
density lipoprotein, VLDL-C cholesterol content in VLDL, VLDL-P VLDL particles, VLDL-TG triglyceride content in VLDL




T1DM)Men Women p Men Women p
VLDL‑P number (nmol/L)
 Total 44.2 (31.5–67.8) 32.0 (23.8–45.0) < 0.001 31.4 (25.0–43.6) 25.9 (21.2–32.6) < 0.001 < 0.001 < 0.001
 Large 1.06 (0.81–1.51) 0.86 (0.60–1.100) < 0.001 0.93 (0.73–1.24) 0.71 (0.56–0.94) < 0.001 0.001 < 0.001
 Medium 4.45 (2.94–6.32) 3.36 (2.36–4.94) < 0.001 3.29 (2.32–4.83) 2.51 (1.68–3.70) < 0.001 < 0.001 < 0.001
 Small 37.5 (27.7–59.6) 27.7 (20.2–39.4) < 0.001 27.3 (22.0–37.6) 22.8 (18.8–28.1) < 0.001 < 0.001 < 0.001
 Ratio large/total 0.024 (0.023–0.027) 0.026 (0.023–0.028) 0.012 0.028 (0.025–0.030) 0.027 (0.025–0.029) 0.002 < 0.001 < 0.001
VLDL‑P composition (mg/dL)
 VLDL‑C 11.30 (6.54–19.40) 7.64 (4.39–12.85) < 0.001 8.99 (5.64–14.60) 6.64 (3.68–9.41) < 0.001 0.006 0.003
 VLDL‑TG 62.1 (44.0–94.0) 45.8 (34.0–63.2) < 0.001 43.9 (35.2–62.4) 36.7 (29.2–45.2) < 0.001 < 0.001 < 0.001
 Ratio VLDL‑C/
VLDL‑TG
0.17 (0.13–0.21) 0.17 (0.12–0.21) 0.451 0.20 (0.15–0.24) 0.17 (0.12–0.22) 0.001 0.001 0.429
VLDL‑P size (nm) 42.08 (41.96–42.24) 42.15 (41.98–42.32) 0.041 42.14 (41.95–42.33) 42.10 (41.87–42.25) 0.03 0.135 0.008
LDL‑P number (nmol/L)
 Total 1413 (1204–1624) 1315 (1137–1506) 0.003 1257 (1128–1383) 1231 (1125–1383) 0.849 < 0.001 0.008
 Large 191.4 (166.2–218.0) 192.2 (169.2–215.0) 0.957 174.8 (159.1–191.5) 176.2 (160.1–200.9) 0.419 < 0.001 < 0.001
 Medium 432.1 (323.7–534.7) 441.1 (351.3–530.3) 0.475 364.8 (304.9–444.2) 387.0 (324.0–489.2) 0.008 < 0.001 < 0.001
 Small 778.7 (692.9–878.4) 671.2 (593.5–761.4) < 0.001 693.4 (635.7–766.2) 672.8 (614.2–733.9) 0.002 < 0.001 0.79
 Ratio small/total 0.56 (0.52–0.60) 0.51 (0.48–0.55) < 0.001 0.56 (0.52–0.60) 0.54 (0.49–0.58) < 0.001 0.607 < 0.001
LDL‑P composition (mg/dL)
 LDL‑C 137.0 (116.9–157.2) 130.7 (111.3–149.6) 0.05 123.2 (110.0–137.2) 121.2 (110.2–136.9) 0.798 < 0.001 0.005
 LDL‑TG 16.5 (13.0–20.1) 16.8 (13.7–20.6) 0.656 14.1 (12.2–16.9) 15.1 (12.7–18.2) 0.013 < 0.001 0.002
 Ratio LDL‑C/
LDL‑TG
8.48 (7.55–9.56) 7.96 (7.00–8.92) 0.003 8.62 (7.61–9.79) 8.07 (7.14–9.31) < 0.001 0.304 0.169
LDL‑P size (nm) 20.9 ± 0.26 21.1 ± 0.24 < 0.001 21.0 ± 0.27 21.1 ± 0.27 < 0.001 0.035 0.01
HDL‑P number (μmol/L)
 Total 27.3 (24.3–29.9) 31.2 (27.8–35.1) < 0.001 29.6 (26.5–33.6) 34.2 (30.8–37.6) < 0.001 < 0.001 < 0.001
 Large 0.25 (0.23–0.29) 0.28 (0.25–0.31) < 0.001 0.26 (0.24–0.29) 0.29 (0.26–0.33) < 0.001 0.015 0.001
 Medium 8.06 (7.18–9.23) 9.99 (8.81–11.48) < 0.001 9.67 (8.58–10.82) 11.8 (10.0–13.7) < 0.001 < 0.001 < 0.001
 Small 18.8 (16.2–21.0) 21.0 (1.83–23.7) < 0.001 19.9 (17.2–22.7) 22.0 (19.5–24.6) < 0.001 0.005 0.004
 Ratio small/total 0.69 (0.65–0.71) 0.67 (0.64–0.70) < 0.001 0.67 (0.64–0.69) 0.65 (0.62–0.67) < 0.001 < 0.001 < 0.001
HDL‑P composition (mg/dL)
 HDL‑C 51.4 (45.8–58.1) 59.8 (53.0–69.7) < 0.001 58.3 (50.9–65.5) 69.0 (61.6–79.6) < 0.001 < 0.001 < 0.001
 HDL‑TG 11.31 (9.05–14.03) 13.6 (11.4–16.6) < 0.001 13.9 (11.5–17.1) 15.4 (13.2–18.8) < 0.001 < 0.001 < 0.001
 Ratio HDL‑C/
HDL‑TG
4.59 (3.64–5.66) 4.40 (3.58–5.42) 0.331 4.22 (3.43–5.14) 4.43 (3.71–5.41) 0.022 0.013 0.782




1446 (1224–1639) 1316 (1130–1513) < 0.001 1260 (1133–1395) 1225 (1123–1369) 0.342 < 0.001 0.003
 Ratio LDL‑P/HDL‑P 52.6 (44.0–63.3) 41.1 (34.2–50.8) < 0.001 41.7 (35.7–49.4) 36.0 (31.6–42.8) < 0.001 < 0.001 < 0.001
 Ratio total‑P/
HDL‑P
54.0 (45.5–65.5) 42.1 (35.3–52.0) < 0.001 43.0 (36.6–51.2) 36.6 (32.4–43.7) < 0.001 < 0.001 < 0.001
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Conventional vs. NMR‑derived LDL‑related parameters
LDL-cholesterol assessed by conventional methods and 
LDL-P measured by NMR spectroscopy were strongly 
correlated in both groups (r = 0.801 and r = 0.789, for 
control and T1DM groups, respectively; Fig.  2). How-
ever, a higher number of LDL particles per mg/dl of 
LDL-cholesterol (ratio LDL-P/LDL-cholesterol) was 
found in the T1DM group (11.71 [10.61–13.07] vs. 
12.19 [11.21–13.65], for the control and T1DM groups, 
respectively; p < 0.001). In fact, when we assessed 
the percentage of participants with concordance in 
LDL-cholesterol and LDL-P levels (< or > 100  mg/dL 
and < or > 1000  nmol/L, respectively), almost twice 
the proportion of participants with T1DM and LDL-
cholesterol < 100  mg/dL had LDL-P > 1000  nmol/L 
(21.2% for the control group vs. 38% for T1DM group; 
p < 0.001; Fig.  2). Significant differences still remained 
after excluding those participants on lipid-lower-
ing drugs (20.5% vs. 29.1%; p = 0.011). Interestingly, 
although the proportion of participants with LDL-
cholesterol < 100  mg/dl was significantly higher in 
the T1DM group (29.1% vs. 44.8%; p < 0.001; Table  1), 
no difference was observed in the proportion with 
LDL-P < 1000 nmol/L (7.8 vs. 7.0%, for the control and 
T1DM group, respectively; p = 0.622).
Discussion
In this large sample of individuals with T1DM, a better 
overall advanced lipoprotein profile was observed com-
pared to non-diabetic counterparts, characterised by 
a decrease in the total amount of atherogenic particles 
(i.e., VLDL-P and LDL-P) and an increase in antiathero-
genic ones (i.e., HDL-P). However, a differential pattern 
in LDL-related variables was shown in this population, 
with a higher number of LDL-P per each mg/dl of con-
ventional LDL-cholesterol, and a worse profile among 
T1DM women (similar small LDL-P than women with-
out diabetes; no differences in total LDL-P compared 
with men with T1DM). To the best of our knowledge, 
this is so far the largest study assessing the differences 
in NMR-assessed lipoprotein profile in a broad range of 
contemporary patients with T1DM.
Differences in NMR advanced lipoprotein profile according 
to T1DM status and gender
In our sample of T1DM individuals from a Mediterra-
nean region of Spain, a decrease in the total number of 
atherogenic lipoproteins and an increase in the antia-
therogenic ones was shown vs. non-diabetic counterparts 
(p < 0.001 for all comparisons, Table 2). However, previ-
ous studies have reported conflicting results, either using 
a b
Fig. 1 Associations between NMR‑assessed advanced lipoprotein profile and clinical and laboratory parameters. a Control Group; b T1DM group. 
Solid and open circles indicate positive and negative relationships, respectively. * Available value in n = 191 controls. † Available value in n = 185 
controls. ACR: albumin‑to‑creatinine ratio; ALAT: alanine aminotransferase: BMI: body mass index; eGFR: estimated glomerular filtration rate; FLI: fatty 
liver index; FPG: fasting plasma glucose; HDL: high‑density lipoprotein; HDL‑C: cholesterol content in HDL; HDL‑P: HDL particles; HDL‑TG: triglyceride 
content in HDL; hsCRP: high sensitivity C‑reactive protein; IS: insulin sensitivity; LDL: low‑density lipoprotein; LDL‑C: cholesterol content in LDL; 
LDL‑P: LDL particles; LDL‑TG: triglyceride content in LDL; NMR: nuclear magnetic resonance; SBP: systolic blood pressure; VLDL: very low‑density 
lipoprotein; VLDL‑C: cholesterol content in VLDL; VLDL‑P: VLDL particles; VLDL‑TG: triglyceride content in VLDL; WBC: white blood cells; WC: waist 
circumference
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conventional biochemical analysis [9], liquid chromatog-
raphy [10, 11], proteomic analysis [29] or RMN-advanced 
procedures [12–16]. Overall, although the majority of the 
studies showed a better overall lipid profile among T1DM 
individuals [9–13, 16], two independent studies suggested 
that this population could have proatherogenic changes 
in the lipoproteins [14, 15]. Specifically, higher amounts 
of total LDL-P and small HDL-P were found in adoles-
cents [15], and an enrichment in triglyceride content (vs. 
cholesterol) in all the lipoprotein classes was found in 
adults with T1DM [14]. In contrast, no sign of the subtle 
proatherogenic changes suggested in the previous stud-
ies [14, 15] was found in our sample, as the triglyceride 
content of the main lipoprotein classes was not increased 
(or even decreased in the case of LDL-P), and the mean 
size of the HDL-P was significantly higher in the T1DM 
group. Some differences between the previous studies 
and ours should be acknowledged, such as the inclusion 
of an older cohort that may not be representative of the 
current management of T1DM (either in glucose or CVD 
risk factor control) [9, 16], the limited sample size [10–
14], or the strict inclusion criteria of the patients [15]. 
Furthermore, underlying dietetic factors should also be 
taken into account. In fact, the Mediterranean diet has 
been associated with an improved lipoprotein profile in 
previous studies [30]. Since the T1DM population from 
our geographical area has been shown to have a greater 
adherence this type of diet [31], this could have influ-
enced our findings in T1DM vs. controls.
The presence of T1DM in females seems to be associ-
ated with a greater proportional CVD risk than in men. 
Thus, a recent meta-analysis showed that women with 
T1DM had roughly a two-fold greater excess risk of fatal 
and non-fatal CVD compared with T1DM men [32]. 
Although some gender-specific pregnancy complica-
tions may help to explain this excess risk [3], lipid fac-
tors may also be involved. In fact, in our contemporary 
sample, T1DM women showed a worse NMR profile, 
Fig. 2 Scatterplots between LDL‑cholesterol measured by conventional methods and LDL‑P measured by NMR spectroscopy and concordance 
according to LDL‑cholesterol < or > 100 mg/dL and LDL‑P < or > 1000 nmol/l in the control (upper) and T1DM group (down)
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characterised by a similar amount of small LDL-P than 
women without T1DM; and the same LDL-P and total 
atherogenic particles (non-HDL-P) than men with 
T1DM (Table  4). In addition, our data further showed 
that the between-gender differences in LDL-P and non-
HDL-P were less pronounced in the T1DM group vs. the 
control group across all the age ranges of the individuals, 
and even T1DM women had significantly higher levels of 
these lipoproteins from the age of 56  years (Additional 
file  5: Fig.  S1). Statin treatment was 5 to sixfold higher 
in the T1DM group vs. the control group and this could 
have influenced the between-group relationships, how-
ever the between-gender differences were less prone to 
being affected by this variable, since statin use was simi-
lar in men and women (Table  4). Our data agree with 
some older studies, which have also pointed out that the 
better lipoprotein profile observed in the T1DM popula-
tion (vs. control) was usually blunted in women [10, 16], 
with similar between-gender levels of total and LDL-cho-
lesterol in T1DM patients [33].
NMR advanced lipoprotein profile and insulin resistance 
surrogates
Insulin resistance is strongly associated with several lipo-
protein profile derangements [34]. Previous NMR studies 
performed in non-diabetic and type 2 diabetes mellitus 
patients have shown that either markers of adiposity or 
several non-invasive scores of fatty liver disease (both 
closely related with insulin resistance) were directly asso-
ciated with VLDL-related variables, and inversely with 
HDL-related variables [27, 28]. In our study, the adipos-
ity marker most closely associated with insulin resist-
ance (i.e. waist circumference) and the most widely used 
fatty liver disease score (i.e. FLI) were the variables most 
strongly associated with the NMR-advanced lipoprotein 
profile, both in T1DM or control individuals (Fig.  1): 
direct correlations were observed with triglyceride-rich 
lipoproteins and small LDL-P, and inverse correlations 
with HDL-P. Further, some T1DM-specific surrogates of 
insulin sensitivity were also associated with these NMR-
parameters. Preliminary previous data in T1DM has also 
shown similar associations between insulin resistance 
markers and a more proatherogenic lipoprotein profile 
[10, 33, 35]; but information regarding NMR-assessed 
analysis has been lacking. Some of these NMR-variables 
observed in our study, previously associated with CVD 
and mortality in T1DM populations [7, 36, 37], could also 
mediate the well-known relationships between insulin 
resistance and vascular complications in T1DM [38–40].
LDL‑related parameters
HbA1c showed a strong and direct association with 
LDL-related variables in our T1DM sample (Fig.  1 and 
Additional file  6: Table  S5), in accordance with previ-
ous studies [33, 35, 41–43]. Specifically, two recent stud-
ies performed in children and young adults with T1DM 
also showed a direct association between glycaemic con-
trol and overall dyslipidaemia [42], and LDL-cholesterol 
(this effect was further modified by proprotein con-
vertase subtilisin/kexin 9 levels) [43]. As is well known, 
LDL-cholesterol has been pointed out as a causal factor 
in the pathogenesis of atherosclerotic CVD in the general 
population [44]. Although the factors involved among 
the T1DM population are more complex [3–5], LDL-
related variables remain as one of the most important 
lipid parameters for CVD risk [6, 45]. In fact, this vari-
able was strongly associated with coronary atherosclero-
sis in a study assessing long-standing T1DM participants 
[46]. Thus, increasing the knowledge of the variables 
associated with LDL-cholesterol levels in this population 
seems to be crucial for CVD risk assessment. Hence, this 
relationship between HbA1c and LDL-related variables 
could also be involved in mediating the well-known asso-
ciation between poor glycaemic control and increased 
CVD among the T1DM population [47].
Discrepancies between conventional LDL-cholesterol 
and NMR-LDL parameters were found in T1DM indi-
viduals. In our sample, the T1DM group showed higher 
NRM-LDL-P vs. conventional LDL-cholesterol compared 
to controls (38% vs. 21.1%; Fig.  2). Some NMR-derived 
LDL variables seem to confer additional benefits in CVD 
risk assessment, beyond conventional measurements 
of LDL-cholesterol [48]. Prospective data in the general 
population also showed that the individuals with discord-
ant values (i.e., those with higher LDL-P in relation to 
conventional LDL-cholesterol values) were those with a 
higher incidence of future CVD events [49, 50]. Thus, the 
increased proportion of T1DM individuals with discord-
ant values between the NMR vs. the conventional analy-
sis could counteract the apparent “normal” conventional 
LDL-cholesterol levels among the T1DM population, and 
may partially explain why LDL-cholesterol could be more 
atherogenic in T1DM [51]. In this sense, the lowered tar-
gets of LDL-cholesterol in T1DM recently released by 
some societies [17] could help to overcome this fact.
Strengths and limitations
Several strengths and limitations of our study deserve 
additional comments. Among the strengths, we included 
a large number of T1DM participants and controls with a 
broad age span. In this regard, we could show the evolu-
tion of the advanced lipoprotein profile in different age 
ranges, for which there is a paucity of data to date. In 
addition, the contemporary T1DM individuals included, 
reflecting the current state-of-art in glucose and CVD 
risk factor management, is a more representative image 
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of the actual T1DM population than the older studies 
assessing the same topic [9, 16]. Finally, we used the most 
robust method available to study lipoprotein metabolism, 
showing many advantages compared with older tests 
[52]. Several limitations should also be acknowledged. 
First, due to the unmatched design, some of the vari-
ables closely related to the lipoprotein profile were dif-
ferent between the T1DM group and the control group. 
In this regard, statin treatment was significantly higher 
in T1DM individuals, which could have influenced our 
results. However, most of our results were adjusted for 
statin treatment, and a sensitivity analysis performed in 
patients without lipid-lowering treatment led to similar 
results (either in the differences between T1DM vs. con-
trols, between-gender differences, or in the correlations 
between NMR-lipoproteins and other clinical and labora-
tory variables). In addition, some studies have suggested 
that individuals with well-controlled T1DM could have 
lower LDL-cholesterol levels than their non-diabetic 
counterparts due to decreases in VLDL production or 
increases in LDL catabolism [53]. Since our sample of 
T1DM participants was fairly controlled (median HbA1c 
of 7.4%), this fact could partially explain our main find-
ings. Second, the inclusion of T1DM participants from 
cohorts with different inclusion criteria could induce 
some bias in the selection of the sample. However, since a 
broad range of participants were included, it could make 
our results more generalizable. Furthermore, because the 
differences in NRM advanced lipoprotein profile between 
T1DM vs. control groups were consistent regardless of 
the study cohort, this further supports our main findings. 
Third, because virtually all of our T1DM participants 
were on insulin analogs, we could not assess whether the 
use of this type of insulin was associated with changes 
in the advanced lipoprotein profile. Since preliminary 
reports have shown a borderline lower CVD mortality 
among T1DM users of this type of therapy [54], it would 
be interesting to study whether this could be mediated 
through an improved lipoprotein profile. Fourth, the 
exclusion of participants without established CVD could 
lead to a selection bias, especially for the T1DM group. 
Thus, the extrapolation of our results to other T1DM 
patients at higher risk should be made with caution. 
Finally, due to our cross-sectional design, causality can-
not be drawn in the associations between advanced lipid 
profile and the other variables.
Conclusions
In our contemporary sample of Mediterranean indi-
viduals with T1DM without CVD, a better overall 
advanced lipoprotein profile vs. non-diabetic partici-
pants was observed. However, although total LDL-P 
was significantly lower, T1DM individuals showed a 
greater prevalence of discordance with conventional 
LDL-cholesterol. Furthermore, a differentiated pat-
tern was observed according to gender, with less pro-
nounced between-group differences in women with 
T1DM (vs. T1DM men). Insulin resistance and glycae-
mic control were associated with a worse lipoprotein 
profile. Further studies are needed to fully elucidate the 
implications of all of these advanced lipoprotein profile 
derangements in the development of CVD events in 
our, and other, T1DM populations.
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